Artivion, Inc. (AORT)
NYSE · Healthcare · Medical Devices
$22.61+1.34%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- Forward P/E
- 30.2
- 52-week range
- $19.16 – $48.25
- 52-week change
- −45.25%
- EPS (trailing)
- −$0.07
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $441M (+13.59%)
- Net income
- $9.8M
- Operating margin
- 7.6%
- Diluted EPS
- $0.21
- Free cash flow
- $840K
From the company’s annual report on SEC EDGAR.
About Artivion, Inc.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries.
Headquarters: Kennesaw, United States · 1,800 employees · artivion.com